The Latest Progress in Thrombosis and Antithrombotics
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".
Deadline for manuscript submissions: closed (20 December 2022) | Viewed by 1994
Special Issue Editors
Interests: acute coronary syndromes; acute heart failure; antithrombotics; atrial fibrillation; atherothrombosis; chronic ischemic heart disease; lipids and atherosclerosis
Special Issue Information
Dear Colleagues,
Thrombosis is the dominant mechanism in several diseases in cardiovascular medicine. Acute coronary syndromes, deep vein thrombosis and pulmonary embolism, and ischemic stroke all have a thrombotic phenomenon as the main mechanism responsible for vessel occlusion, ischemia and cellular necrosis, all leading to death in most patients.
Antithrombotic therapy, namely antiplatelets and anticoagulants, is the cornerstone of medical treatment in those situations. With or without revascularization, all forms of vascular disease, acute or chronic, require antithrombotics, frequently in combination. The last two decades have been marked by great progress with new drugs and new concepts. Dual antiplatelet therapy and, more recently, the dual pathway of thrombus inhibition are two examples of this success. New P2Y12 inhibitors, new direct acting anticoagulants, very low dose of rivaroxaban, and the very new factor XI inhibitors are all representing big steps toward better healthcare with a great impact on quality of life and life prolongation.
In the current Special Issue of Life, authors were invited to review the mechanisms of thrombus formation as well as the pharmacological background of commonly used antithrombotic drugs, as well as the different concepts in this field. Inflammation as an important mechanism of atherosclerosis has not been forgotten. In the last few years, clinical trials have been moving toward new directions. New methodologies and new paradigms are redirecting clinical trials for a more efficacious performance, and clinicians should be aware of this shift.
Dr. João Morais
Dr. Bianca Rocca
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- thrombosis
- antithrombotics
- antplatelets
- anticoagulants
- inflammation and thrombosis
- pathophysiology of thrombosis
- pharmacology of antithrombotics
